Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis.

ABSTRACT:

Background

Few data exist on how ofatumumab treatment impacts SARS-CoV-2 booster vaccination response.

Methods

KYRIOS is an ongoing prospective open-label multicenter study on the response to initial and booster SARS-CoV-2 mRNA vaccination before or during ofatumumab treatment in relapsing MS patients. The results on the initial vaccination cohort have been published previously. Here, we describe 23 patients who received their initial vaccination outside of the study but booster vaccination during the study. Additionally, we report the booster results of two patients in the initial vaccination cohort. The primary endpoint was SARS-CoV-2-specific T-cell response at month 1. Furthermore, serum total and neutralizing antibodies were measured.

Results

The primary endpoint

SUBMITTER: Ziemssen T 

PROVIDER: S-EPMC10223661 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature